Kageler L, Aquilanti E. Discovery of telomerase inhibitors: existing strategies and emerging innovations. Biochemical Society transactions. 2024;52(4):1957-1968. doi:10.1042/BST20230264
Rahme GJ, Gaskell E, Bernstein BE. GABPβ1L Wakes Up TERT. Cancer Cell. 2018;34(3):358-360. doi:10.1016/j.ccell.2018.08.011
Han S, Zhao BS, Myers SA, Carr SA, He C, Ting AY. RNA-protein interaction mapping via MS2- or Cas13-based APEX targeting. Proc Natl Acad Sci U S A. 2020;117(36):22068-22079. doi:10.1073/pnas.2006617117
Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A. 2005;102(17):5992-7. doi:10.1073/pnas.0502267102
Kwong LN, Zou L, Chagani S, et al. Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep. 2017;19(7):1304-1312. doi:10.1016/j.celrep.2017.04.065
Gopal RK, Kübler K, Calvo SE, et al. Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell. 2018;34(2):242-255.e5. doi:10.1016/j.ccell.2018.06.013
Juratli TA, McCabe D, Nayyar N, et al. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136(5):779-792. doi:10.1007/s00401-018-1899-7
Stern JL, Paucek RD, Huang FW, et al. Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes. Cell Rep. 2017;21(13):3700-3707. doi:10.1016/j.celrep.2017.12.001
Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004;64(24):8867-75. doi:10.1158/0008-5472.CAN-04-2938
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957-9. doi:10.1126/science.1229259